505 related articles for article (PubMed ID: 18534438)
1. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery.
; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA
J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis.
Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI
Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials.
Friedman RJ; Dahl OE; Rosencher N; Caprini JA; Kurth AA; Francis CW; Clemens A; Hantel S; Schnee JM; Eriksson BI;
Thromb Res; 2010 Sep; 126(3):175-82. PubMed ID: 20434759
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran etexilate for prevention of venous thromboembolism.
Eikelboom JE; Weitz JI
Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179
[No Abstract] [Full Text] [Related]
5. Dabigatran: new drug. Continue to use heparin, a better-known option.
Prescrire Int; 2009 Jun; 18(101):97-9. PubMed ID: 19637411
[TBL] [Abstract][Full Text] [Related]
6. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR;
Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate: pivotal trials for venous thromboembolism prophylaxis after hip or knee arthroplasty.
Eriksson BI; Friedman RJ
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():25S-31S. PubMed ID: 19648146
[TBL] [Abstract][Full Text] [Related]
8. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Eriksson BI; Dahl OE; Huo MH; Kurth AA; Hantel S; Hermansson K; Schnee JM; Friedman RJ;
Thromb Haemost; 2011 Apr; 105(4):721-9. PubMed ID: 21225098
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran etexilate for the prophylaxis of venous thromboembolism after hip or knee replacement rationale for dose regimen.
Dahl OE
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():17S-24S. PubMed ID: 19696041
[TBL] [Abstract][Full Text] [Related]
10. Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.
Raskob GE; Gallus AS; Pineo GF; Chen D; Ramirez LM; Wright RT; Lassen MR
J Bone Joint Surg Br; 2012 Feb; 94(2):257-64. PubMed ID: 22323697
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgery.
Wolowacz SE; Roskell NS; Maciver F; Beard SM; Robinson PA; Plumb JM; Dolan G; Brenkel IJ
Clin Ther; 2009 Jan; 31(1):194-212. PubMed ID: 19243718
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a single technology appraisal.
Holmes M; Carroll C; Papaioannou D
Health Technol Assess; 2009 Sep; 13 Suppl 2():55-62. PubMed ID: 19804690
[TBL] [Abstract][Full Text] [Related]
13. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial.
Eriksson BI; Dahl OE; Büller HR; Hettiarachchi R; Rosencher N; Bravo ML; Ahnfelt L; Piovella F; Stangier J; Kälebo P; Reilly P;
J Thromb Haemost; 2005 Jan; 3(1):103-11. PubMed ID: 15634273
[TBL] [Abstract][Full Text] [Related]
14. Enoxaparin versus dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty: Results of separate pooled analyses of phase III multicenter randomized trials.
Huisman MV; Quinlan DJ; Dahl OE; Schulman S
Circ Cardiovasc Qual Outcomes; 2010 Nov; 3(6):652-60. PubMed ID: 20923996
[TBL] [Abstract][Full Text] [Related]
15. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Weitz JI; Cao C; Eriksson BI; Fisher W; Kupfer S; Raskob G; Spaeder J; Turpie AG
Thromb Haemost; 2010 Dec; 104(6):1150-7. PubMed ID: 20886185
[TBL] [Abstract][Full Text] [Related]
16. [Thrombin inhibitor shows stable safety profile in the practice].
MMW Fortschr Med; 2008 Dec; 150(51-52):38-9. PubMed ID: 19149309
[No Abstract] [Full Text] [Related]
17. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty.
Borris LC
Arch Orthop Trauma Surg; 2010 May; 130(5):583-9. PubMed ID: 19565250
[TBL] [Abstract][Full Text] [Related]
18. Dabigatran etexilate prevents venous thromboembolism after total knee arthroplasty in Japanese patients with a safety profile comparable to placebo.
Fuji T; Fuijita S; Ujihira T; Sato T
J Arthroplasty; 2010 Dec; 25(8):1267-74. PubMed ID: 19854610
[TBL] [Abstract][Full Text] [Related]
19. Dabigatran etexilate: future directions in anticoagulant treatment.
Schulman S; Reilly PA
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
[TBL] [Abstract][Full Text] [Related]
20. Prevention of postoperative venous thromboembolism in Japanese patients undergoing total hip or knee arthroplasty: two randomized, double-blind, placebo-controlled studies with three dosage regimens of enoxaparin.
Fuji T; Ochi T; Niwa S; Fujita S
J Orthop Sci; 2008 Sep; 13(5):442-51. PubMed ID: 18843459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
